The effect of comorbid conditions on hemodialysis access patency.

Vascular access complications are a continuing source of hospitalization and morbidity in chronic dialysis patients. Several factors have been identified that are associated with complications in patients with native vein and prosthetic bridge arteriovenous graft fistulas. Early failure of native vein arteriovenous fistulas most consistently are related to small blood vessels. It remains unclear whether other comorbid factors play a role in complications of this fistula type. Prosthetic bridge fistulas are frequently placed in the United States and are associated with frequent complications. Factors most consistently associated with higher complication rates are diabetes mellitus, older age, and black race. Antiphospholipid antibody-associated syndromes and erythropoietin therapy have also been suggested as contributing factors. In addition, elevated lipoprotein(a) and hypoalbuminemia have been found to be associated with an increase of prosthetic graft thrombosis in white and Hispanic dialysis patients. This information strongly suggests that fistula complications are multifactorial. An improved understanding of the mechanisms of these associations may aid in the delineation of the pathogenesis and an improvement in the outcome of this important problem.

[1]  J. Alexander,et al.  Polytetrafluoroethylene graft survival in hemodialysis. , 1983, JAMA.

[2]  R. Heyka,et al.  Lipoprotein(a) Is an Independent Risk Factor for Cardiovascular Disease in Hemodialysis Patients , 1992, Circulation.

[3]  R. Lawn,et al.  Lipoprotein(a) and atherosclerosis. , 1991, Annals of internal medicine.

[4]  F. Moldenhauer,et al.  Anticardiolipin antibodies and lupus anticoagulant in end-stage renal disease. , 1991, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[5]  P. Goldwasser,et al.  Prealbumin and lipoprotein(a) in hemodialysis: relationships with patient and vascular access survival. , 1993, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[6]  B. Skipper,et al.  Bovine carotid artery heterografts versus polytetrafluoroethylene grafts. A prospective, randomized study. , 1983, American journal of surgery.

[7]  P. Vereerstraeten,et al.  Nine years' experience with internal arteriovenous fistulas for haemodialysis: A study of some factors influencing the results , 1977, The British journal of surgery.

[8]  P. Bell,et al.  Prospective study of dialysis fistulas: Problem patients and their treatment , 1982, The British journal of surgery.

[9]  I. Macdougall,et al.  Coagulation studies and fistula blood flow during erythropoietin therapy in haemodialysis patients. , 1991, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[10]  H. Kwaan,et al.  Changes in platelet function during hemodialysis. , 1978, The Journal of laboratory and clinical medicine.

[11]  A. Roberts,et al.  Pharmacomechanical thrombolysis and angioplasty in the management of clotted hemodialysis grafts: early and late clinical results. , 1991, Radiology.

[12]  P. Halushka,et al.  Increased platelet thromboxane synthesis in diabetes mellitus. , 1981, The Journal of laboratory and clinical medicine.

[13]  F. Schillinger,et al.  Post catheterisation vein stenosis in haemodialysis: comparative angiographic study of 50 subclavian and 50 internal jugular accesses. , 1991, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[14]  R. Blumoff,et al.  Vascular access in a University transplant and dialysis program. Results, costs, and manpower implications. , 1977, Archives of surgery.

[15]  C. Ponticelli,et al.  IMPROVEMENT IN THE HAEMOSTATIC DEFECT OF URAEMIA AFTER TREATMENT WITH RECOMBINANT HUMAN ERYTHROPOIETIN , 1987, The Lancet.

[16]  D. Churchill,et al.  Canadian Hemodialysis Morbidity Study. , 1992, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[17]  R. Shalhoub.  Pathogenesis of lipoid nephrosis: a disorder of T-cell function. , 1974, Lancet.

[18]  S. Santoro,et al.  Antiphospholipid antibodies: anticardiolipin and the lupus anticoagulant in systemic lupus erythematosus (SLE) and in non-SLE disorders. Prevalence and clinical significance. , 1990, Annals of internal medicine.

[19]  R. Abbate,et al.  Platelet synthesis of cyclooxygenase and lipoxygenase products in type I and type II diabetes. , 1988, Prostaglandins, leukotrienes, and essential fatty acids.

[20]  L. R. King,et al.  Comparison of autogenous fistula versus expanded polytetrafluoroethylene graft fistula for angioaccess in hemodialysis. , 1986, American journal of surgery.

[21]  E. Ernst,et al.  Fibrinogen as a Cardiovascular Risk Factor , 1993, Annals of Internal Medicine.

[22]  M. Hicks,et al.  The importance of preoperative evaluation of the subclavian vein in dialysis access planning. , 1991, AJR. American journal of roentgenology.

[23]  L. Wilhelmsen,et al.  Lipoprotein (a) and coronary heart disease: a prospective case-control study in a general population sample of middle aged men. , 1990, BMJ.

[24]  G. Neild,et al.  Recombinant human erythropoietin shortens the uraemic bleeding time without causing intravascular haemostatic activation. , 1990, Thrombosis research.

[25]  D. Baim,et al.  Restenosis after Arterial Injury Caused by Coronary Stenting in Patients with Diabetes Mellitus , 1993, Annals of Internal Medicine.

[26]  D. Windus.  Permanent vascular access: a nephrologist's view. , 1993, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[27]  R M Hakim,et al.  Vascular Access for Hemodialysis Patency Rates and Results of Revision , 1985, Annals of surgery.

[28]  J. Ragsdale,et al.  Does the use of erythropoietin in hemodialysis patients increase dialysis graft thrombosis rates? , 1993, American journal of surgery.

[29]  E. Schuman,et al.  Long-term patency of polytetrafluoroethylene graft fistulas. , 1988, American journal of surgery.

[30]  J. Berlin,et al.  Hemodialysis vascular access morbidity in the United States. , 1993, Kidney international.

[31]  R. Marcén,et al.  Lupus-like in vitro anticoagulant activity in end-stage renal disease. , 1988, Nephron.

[32]  G. Sicard,et al.  Bovine carotid artery and expanded polytetrafluroethylene grafts for hemodialysis vascular access. , 1980, The Journal of surgical research.

[33]  W. J. Johnson,et al.  Effects of recombinant human erythropoietin on cerebral and cutaneous blood flow and on blood coagulability. , 1990, Kidney international.

[34]  A. Laupacis,et al.  Erythropoietin for anaemia in haemodialysis patients: results of a maintenance study (the Canadian Erythropoietin Study Group). , 1992, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[35]  J. Delmez,et al.  Prosthetic fistula survival and complications in hemodialysis patients: effects of diabetes and age. , 1992, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[36]  B. G. Brown,et al.  Intimal fibromuscular hyperplasia at the venous anastomosis of PTFE grafts in hemodialysis patients. Clinical, immunocytochemical, light and electron microscopic assessment. , 1989, Circulation.

[37]  G. Zibari,et al.  Complications from permanent hemodialysis vascular access. , 1988, Surgery.

[38]  D. Wagner.  Cell biology of von Willebrand factor. , 1990, Annual review of cell biology.